诺华制药 NVS 深 沪
已收盘 12-19 16:00:00 美东时间
136.07
+0.790
+0.58%
华盛通- 最 高137.40
- 今 开134.875
- 成交量 102.37万股
- 最 低 128.75
- 昨 收 135.28
- 总市值 3011.23亿
- 52周最高 137.40
- 市盈率 静 12.80
- 换手率 0.05%
- 52周最低 97.06
- 委 比 60.00%
- 总股本 22.13亿
- 历史最高 137.40
- 量 比 0.66
- 振 幅 6.39%
- 历史最低 12.4187
- 每 手 1
- 风险率 10.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts
Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
今天 04:17
White House Readies Drug Price Deals With AbbVie, Novartis, Roche
AbbVie and other drugmakers may announce U.S. drug pricing deals on Friday as the White House pushes lower prices and Medicare payment reforms.
12-18 23:14
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.
12-09 20:51
JP Morgan Upgrades Novartis to Overweight
JP Morgan analyst Richard Vosser upgrades Novartis (NYSE:NVS) from Neutral to Overweight.
12-08 21:14
Price Over Earnings Overview: Novartis
In the current session, the stock is trading at $133.84, after a 1.06% spike. O...
12-06 05:00
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.
11-21 01:43
Novartis Announces Plans To Build Flagship Manufacturing Hub In North Carolina
Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030 Enables manufacturing of medicines across company's main therapeutic areas in one
11-20 01:34
Competition Bureau Expands Its Investigation Into BWX Technologies' Acquisition Of Kinectrics
https://www.canada.ca/en/competition-bureau/news/2025/11/competition-bureau-expands-its-investigation-into-bwx-technologies-acquisition-of-kinectrics.html?utm_source=miragenews&utm_medium=miragenews&utm_campaign=
11-20 01:17
Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.
11-14 01:33
Novartis Opens New Production Site In Carlsbad, California
Novartis, a leading global innovative medicines company, today announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. This state-of-the-art site
11-10 22:32
